BRPI0512182A - método para o tratamento de condições e desordens do sistema nervoso - Google Patents

método para o tratamento de condições e desordens do sistema nervoso

Info

Publication number
BRPI0512182A
BRPI0512182A BRPI0512182-5A BRPI0512182A BRPI0512182A BR PI0512182 A BRPI0512182 A BR PI0512182A BR PI0512182 A BRPI0512182 A BR PI0512182A BR PI0512182 A BRPI0512182 A BR PI0512182A
Authority
BR
Brazil
Prior art keywords
disorders
nervous system
azabicyclo
hexane
system conditions
Prior art date
Application number
BRPI0512182-5A
Other languages
English (en)
Inventor
Magid A Abou-Gharbia
Arthur Jay Cohn
Darlene Coleman Deecher
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0512182A publication Critical patent/BRPI0512182A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODO PARA O TRATAMENTO DE CONDIçõES E DESORDENS DO SISTEMA NERVOSO. A presente invenção refere-se a racemic 1-(3,4-diclorofenil)-3- azabiciclo¢3.1.0!hexano racêmico, (+)-1 -(3,4-diclorofenil)-3-azabiciclo¢3.1.0!hexano, 1-( 4-mmetilfenil)-3-azabiciclo¢3.1.0!hexano racêmico e (+)-1 -(4-metilfenil)-3-azabiciclo-¢3.1.0!hexano, e a métodos de seu uso para o tratamento de desordens ou condições do sistema nervoso, incluindo, inter alia, sintomas vaso motores (VMS) e dor crónica.
BRPI0512182-5A 2004-07-22 2005-07-21 método para o tratamento de condições e desordens do sistema nervoso BRPI0512182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59010304P 2004-07-22 2004-07-22
PCT/US2005/025978 WO2006012477A1 (en) 2004-07-22 2005-07-21 Method for treating nervous system disorders and conditions

Publications (1)

Publication Number Publication Date
BRPI0512182A true BRPI0512182A (pt) 2008-02-19

Family

ID=35385504

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512182-5A BRPI0512182A (pt) 2004-07-22 2005-07-21 método para o tratamento de condições e desordens do sistema nervoso

Country Status (14)

Country Link
US (3) US20060020014A1 (pt)
EP (1) EP1773322A1 (pt)
JP (1) JP2008507552A (pt)
KR (1) KR20070034129A (pt)
CN (2) CN101014337A (pt)
AU (1) AU2005266997A1 (pt)
BR (1) BRPI0512182A (pt)
CA (1) CA2574420A1 (pt)
IL (1) IL180730A0 (pt)
MX (1) MX2007000851A (pt)
NO (1) NO20070915L (pt)
RU (1) RU2007102291A (pt)
WO (1) WO2006012477A1 (pt)
ZA (2) ZA200700580B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
EP1904059A2 (en) * 2005-07-21 2008-04-02 Wyeth a Corporation of the State of Delaware Method for treating nervous system disorders and conditions
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
RU2395313C2 (ru) * 2008-10-15 2010-07-27 Татьяна Прохоровна Тетерина Способ коррекции синдрома дефицита внимания и гиперактивности
US9566264B2 (en) * 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
WO2020142545A1 (en) 2018-12-31 2020-07-09 Ethismos Research, Inc. Novel methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3166571A (en) * 1962-06-06 1965-01-19 American Cyanamid Co 1-phenyl-1, 2-cyclopropane dicarboximides
US3344026A (en) * 1966-05-16 1967-09-26 American Cyanamid Co Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression
US3892772A (en) * 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
GR72713B (pt) * 1976-09-15 1983-12-01 American Cyanamid Co
US4118417A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
EP0114033B1 (de) * 1982-12-21 1988-10-12 Ciba-Geigy Ag Substituierte Azabicycloalkane, ihre Verwendung, pharmazeutische Präparate, welche diese Verbindungen enthalten, und Verfahren zur Herstellung dieser Verbindungen
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
DE19919336A1 (de) * 1999-04-27 2000-11-16 Consortium Elektrochem Ind Verfahren zur Ringspaltung von Thiazolidinderivaten
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
DE60221642T3 (de) * 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-desmethyl-venlafaxine succinat salz
EP1266659A1 (en) * 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7030164B2 (en) * 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
CA2574310A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions

Also Published As

Publication number Publication date
ZA200700580B (en) 2010-07-28
KR20070034129A (ko) 2007-03-27
CN101014337A (zh) 2007-08-08
NO20070915L (no) 2007-04-20
AU2005266997A1 (en) 2006-02-02
US20060020014A1 (en) 2006-01-26
WO2006012477A1 (en) 2006-02-02
IL180730A0 (en) 2007-07-04
MX2007000851A (es) 2007-03-26
US20110124699A1 (en) 2011-05-26
ZA200700583B (en) 2010-07-28
JP2008507552A (ja) 2008-03-13
WO2006012477B1 (en) 2006-05-18
US20120190721A1 (en) 2012-07-26
CN101022794A (zh) 2007-08-22
EP1773322A1 (en) 2007-04-18
RU2007102291A (ru) 2008-08-27
CA2574420A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
ATE425965T1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DK1879873T3 (da) Neuroterapeutiske azolforbindelser
WO2006002121A3 (en) Compounds and methods for treating seizure and paroxysmal disorders
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
BRPI0718437A2 (pt) Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
ATE527016T1 (de) System zur überwachung oder behandlung von erkrankungen des nervensystems
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
EP1638443A4 (en) ISOFORMS OF BRAIN NATRIURETIC PEPTIDE
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
CY1107274T1 (el) Παραγωγα αλφα-αμινοαμιδιου χρησιμα σαν παραγοντες κατα της ημικρανιας
MX2011001384A (es) Composiciones y metodos para tratar trastornos psiquiatricos.
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
WO2008036846A3 (en) Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
EP1838381A4 (en) DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF NECK, NOSE AND EAR DISEASES
BRPI0512182A (pt) método para o tratamento de condições e desordens do sistema nervoso
NO20070912L (no) Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
DE602005025941D1 (de) Alpha-Aminoamid-Derivate zur Behandlung von Suchtstörungen
ATE457309T1 (de) Modulatoren von peripheren 5-ht-rezeptoren
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
DE602004029671D1 (de) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicycloä3.2.0üheptan mit analgetischer wirksamkeit
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.